NSD1 Mutations and Pediatric High-Grade Gliomas: A Comparative Genomic Study in Primary and Recurrent Tumors

Pediatric high-grade gliomas represent a heterogeneous group of tumors with a wide variety of molecular features. We performed whole exome sequencing and methylation profiling on matched primary and recurrent tumors from four pediatric patients with hemispheric high-grade gliomas. Genetic analysis showed the presence of some variants shared between primary and recurrent tumors, along with other variants exclusive of primary or recurrent tumors. NSD1 variants, all novel and not previously reported, were present at high frequency in our series (100%) and were all shared between the samples, independently of primary or recurrence. For every variant, in silico prediction tools estimated a high probability of altering protein function. The novel NSD1 variant (c.5924T > A; p.Leu1975His) was present in one in four cases at recurrence, and in two in four cases at primary. The novel NSD1 variant (c.5993T > A; p.Met1998Lys) was present in one in four cases both at primary and recurrence, and in one in four cases only at primary. The presence of NSD1 mutations only at recurrence may suggest that they can be sub-clonal, while the presence in both primary and recurrence implies that they can also represent early and stable events. Furthermore, their presence only in primary, but not in recurrent tumors, suggest that NSD1 mutations may also be influenced by treatment.

[1]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[2]  B. Pollo,et al.  Correlation Between Immunohistochemistry and Sequencing in H3G34-Mutant Gliomas , 2020, The American journal of surgical pathology.

[3]  M. Heuser,et al.  Targeted Inhibition of the NUP98-NSD1 Fusion Oncogene in Acute Myeloid Leukemia , 2020, Cancers.

[4]  David T. W. Jones,et al.  A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR. , 2020, Neuro-oncology.

[5]  Hsiang-Cheng Chi,et al.  DOCK6 promotes chemo- and radioresistance of gastric cancer by modulating WNT/β-catenin signaling and cancer stem cell traits , 2020, Oncogene.

[6]  P. Varlet,et al.  The pediatric supratentorial MYCN-amplified high-grade gliomas methylation class presents the same radiological, histopathological and molecular features as their pontine counterparts , 2020, Acta Neuropathologica Communications.

[7]  M. Janiszewska The microcosmos of intratumor heterogeneity: the space-time of cancer evolution , 2019, Oncogene.

[8]  Fan Zhang,et al.  CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway , 2019, Journal of Experimental & Clinical Cancer Research.

[9]  Arun K. Ramani,et al.  Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas , 2019, Nature Communications.

[10]  M. Tartaglia,et al.  Role of DNA Methylation Profile in Diagnosing Astroblastoma: A Case Report and Literature Review , 2019, Front. Genet..

[11]  Martin Sill,et al.  Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience , 2018, Acta Neuropathologica.

[12]  Till Acker,et al.  DNA methylation-based classification of central nervous system tumours , 2018, Nature.

[13]  J. Finlay,et al.  Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas , 2017, Acta neuropathologica communications.

[14]  A. Gentles,et al.  NSD1 inactivation defines an immune cold, DNA hypomethylated subtype in squamous cell carcinoma , 2017, Scientific Reports.

[15]  Kun Mu,et al.  Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma , 2017, Cancer cell.

[16]  David T. W. Jones,et al.  H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers , 2017, Acta Neuropathologica.

[17]  David T. W. Jones,et al.  Pediatric high-grade glioma: biologically and clinically in need of new thinking , 2016, Neuro-oncology.

[18]  Hyung-Goo Kim,et al.  Steric Clash in the SET Domain of Histone Methyltransferase NSD1 as a Cause of Sotos Syndrome and Its Genetic Heterogeneity in a Brazilian Cohort , 2016, Genes.

[19]  A L Turinsky,et al.  NSD1 mutations generate a genome-wide DNA methylation signature , 2015, Nature Communications.

[20]  P. Varlet,et al.  Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes , 2015, Acta Neuropathologica.

[21]  M. Skalej,et al.  DOCK6 Mutations Are Responsible for a Distinct Autosomal‐Recessive Variant of Adams–Oliver Syndrome Associated with Brain and Eye Anomalies , 2015, Human mutation.

[22]  Yusuke Nakamura,et al.  The NSD family of protein methyltransferases in human cancer. , 2015, Epigenomics.

[23]  Satoru Miyano,et al.  Mutational landscape and clonal architecture in grade II and III gliomas , 2015, Nature Genetics.

[24]  Jill S. Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012 , 2015, Neuro-oncology.

[25]  Volker Hovestadt,et al.  Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity , 2015, Acta Neuropathologica.

[26]  Chris Jones,et al.  Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma , 2014, Nature Reviews Cancer.

[27]  Peter Canoll,et al.  MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma , 2014, Proceedings of the National Academy of Sciences.

[28]  K. Döhner,et al.  Tracing the development of acute myeloid leukemia in CBL syndrome. , 2014, Blood.

[29]  Steven J. M. Jones,et al.  Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma , 2014, Science.

[30]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[31]  V. Amani,et al.  Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymoma , 2014, Acta Neuropathologica.

[32]  T. Ogata,et al.  Akt and PP2A Reciprocally Regulate the Guanine Nucleotide Exchange Factor Dock6 to Control Axon Growth of Sensory Neurons , 2013, Science Signaling.

[33]  V. P. Collins,et al.  Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics , 2013, Proceedings of the National Academy of Sciences.

[34]  Darren Hargrave,et al.  Paediatric and adult malignant glioma: close relatives or distant cousins? , 2012, Nature Reviews Clinical Oncology.

[35]  S. Scherer,et al.  Clonal Selection Drives Genetic Divergence of Metastatic Medulloblastoma , 2012, Nature.

[36]  J. Rice,et al.  Role for the nuclear receptor-binding SET domain protein 1 (NSD1) methyltransferase in coordinating lysine 36 methylation at histone 3 with RNA polymerase II function , 2010, Proceedings of the National Academy of Sciences.

[37]  F. Giangaspero,et al.  Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas , 2010, Journal of Neuro-Oncology.